Quil A

05/01/2009 - "In conclusion, these data demonstrate that although recombinant SsEno formulated with Quil A triggers a strong antibody response, it does not confer effective protection against infection with S. "
02/01/2003 - "Solubilised inclusion bodies are injected, together with Quil A, subcutaneously on two occasions 1 month or more apart, and induce protection against infection which lasts for at least 12 months. "
01/01/2009 - "The effect of Quil A adjuvant on the course of experimental Fasciola hepatica infection in sheep."
08/01/2007 - "These data demonstrate that recombinant Sao formulated with Quil A triggers strong opsonizing antibody responses which confer efficient immunity against challenge infection with heterologous S. "
06/30/2007 - "gondii infection through induction of a Th1-type immune response, and that protective immunity is accelerated by the modulating effects of Quil A."

09/07/2010 - "The effects of a novel adjuvant composed of Quil A, cholesterol, dimethyl dioctadecyl ammonium bromide, and Carbopol (QCDC) on protective immunity against avian coccidiosis following immunization with an Eimeria recombinant protein were determined. "
03/01/2012 - "This study investigated the ability of two novel adjuvant formulations, QCDC (Quil A/cholesterol/DDA/ Carbopol) and QCDCR (QCDC/Bay R1005), in combination with a recombinant profilin vaccine, to modulate host protective immunity and to alter gene expression during experimental avian coccidiosis. "
11/16/2010 - "Our previous study demonstrated that chickens immunized subcutaneously with an Eimeria recombinant profilin protein vaccine emulsified in a Quil A/cholesterol/DDA/Carbopol (QCDC) adjuvant developed partial protection against experimental avian coccidiosis compared with animals immunized with profilin alone. "
06/01/2012 - "The effects against avian coccidiosis of two novel adjuvants, Quil A/cholesterol/dimethyl dioctadecyl ammonium bromide/Carbopol (QCDC) and QCDC/Bay R1005 (R)/cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (CpG ODN [T]) (QCDCRT) emulsified with profilin, a conserved Eimeria recombinant protein, were determined in broiler chickens. "

01/01/2020 - "Aged 21-month-old mice were found to be completely protected against live influenza challenge after vaccination with the MNPs adjuvanted with the Quil-A/cGAMP combination (5 µg each) and demonstrated significantly reduced morbidity compared to the observed responses in these mice vaccinated with unadjuvanted MNPs. "
10/01/1996 - "A challenge study was conducted to evaluate the safety and efficacy of an inactivated influenza H3N2 virus vaccine combined with Quil A/Alhydrogel mixture under controlled conditions in piglets. "
04/30/2012 - "We found, after vaccinating mice, that anti-influenza IgG antibody and haemagglutinin inhibition assay titre response induced by the Nanopatch (with delivered dose of 6.5ng of vaccine and 1.4μg of Quil-A) were equivalent to that of the conventional intramuscular injection using needle and syringe (6000ng of vaccine injected without adjuvant). "

06/30/2007 - "Immunization with rSAG3 or rSAG3/Quil A resulted in significantly more survival days and fewer brain cysts after challenge with T. "
05/25/2012 - "The results of this study suggest that rhoptry proteins plus Quil-A stimulated humoral, local, and systemic immune responses, which were able to partially protect the brain from cyst formation."
11/15/1991 - "This protein, when administered to outbred mice in the presence of the saponin Quil A, is able to induce almost 100% protection against acute infection without evidence of intracerebral cyst development. "

01/01/1977 - "VI. The adjuvant activity of quil A in trivalent vaccination of cattle and guinea pigs against foot-and-mouth disease."
01/01/1977 - "IV. Evaluation of the adjuvant quil A in the vaccination of cattle against foot-and-mouth disease."
01/01/2022 - "Keywords: foot-and-mouth disease; vaccine; adjuvant; Quil-A; E. "
06/15/2007 - "Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil A."
06/15/2007 - "In model animal experiment B, ICR mice were immunized with foot-and-mouth disease virus (FMDV) antigens or with a commercially available oil adjuvanted foot-and-mouth disease (FMD) vaccine (type O) alone or mixed with Quil A. "